KMTS vs NTLA: fair value comparison
Kestra Medical Technologies, Ltd. and Intellia Therapeutics, Inc. · Updated 2026-10-19
KMTS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NTLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, KMTS currently ranks higher by quality score.
| KMTS | NTLA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $27.24 | $11.42 |
| 12-month range | $17.87–$28.68 | $8.04–$25.89 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #189 of 301 Healthcare | #191 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: KMTS fair value analysis · NTLA fair value analysis